Conserved host-pathogen interactions identify novel treatment options in betacoronavirus infections

Soeren Lukassen, Roland EilsSignal 2021 · DOI · OpenAlex

Abstract

This study maps the comparative protein-protein interaction (PPI) landscape of three pathogenic betacoronaviruses: SARS-CoV-1, SARS-CoV-2, and MERS-CoV. By identifying conserved host proteins—termed "dependency factors"—that these viruses hijack for replication, researchers have uncovered stable therapeutic targets less prone to viral mutational escape. Functional genomic screens and structural analysis identified key interactions, such as the suppression of innate immunity by viral ORF9b via the mitochondrial receptor TOM70. Furthermore, the study identifies PGES-2 and Sigma-1 receptors as druggable host factors. Retrospective clinical analysis of over 700,000 patients suggests that existing medications targeting these factors, including indomethacin and typical antipsychotics, are associated with improved clinical outcomes in COVID-19 patients.

Introduction

The rapid mutation of viral proteins often leads to the development of drug resistance, limiting the long-term efficacy of direct-acting antivirals. To address this, researchers have turned to the "host-pathogen interactome," focusing on the physical interactions between viral proteins and the more slowly evolving human host machinery. By identifying host factors essential for viral replication (dependency factors) that are shared across different betacoronaviruses, it is possible to develop broad-spectrum, "future-proof" therapeutic strategies.

Methods

The researchers employed a multi-disciplinary approach to map and validate the betacoronavirus interactome:

  1. Interactome Mapping: Mass spectrometry was used to identify host proteins binding to tagged viral proteins from SARS-CoV-1, SARS-CoV-2, and MERS-CoV in HEK293T cells.
  2. Functional Screening: siRNA and CRISPR-Cas9 genetic screens in lung and gut cell lines identified host proteins whose absence significantly reduced viral replication.
  3. Structural Biology: Cryo-electron microscopy (CryoEM) characterized the physical interface between specific viral and host proteins, notably the ORF9b-TOM70 complex.
  4. Clinical Validation: A retrospective analysis of medical billing records for 738,933 COVID-19 patients was conducted to evaluate the real-world impact of drugs targeting the identified host factors.
Comparative interactome mapping strategy. The study analyzed protein-protein interactions between three betacoronaviruses and host proteins in HEK293T cells to identify conserved dependency factors.

Key Insights and Results

Conservation of Viral-Host Interactions

The study revealed that while viral sequences diverge, the functional groups of host proteins they interact with remain highly conserved. SARS-CoV-1 and SARS-CoV-2 exhibit more similar interaction profiles compared to MERS-CoV. A critical finding was the identification of 12 host proteins that interact with the viral protein NSP7 across multiple coronaviruses.

Mechanisms of Immune Evasion and Druggable Targets

A major discovery involved the viral protein ORF9b, which binds to TOM70, a mitochondrial import receptor. This interaction disrupts the IFN-β signaling pathway, effectively "short-circuiting" the host's innate immune response.

Additionally, the study highlighted two specific host factors with existing FDA-approved inhibitors:

  • PGES-2: Involved in prostaglandin synthesis and inhibited by the anti-inflammatory drug indomethacin.
  • Sigma-1 Receptor: A target for typical antipsychotic medications.
Molecular mechanisms of viral immune evasion and therapeutic targeting. (c) Viral ORF9b inhibits the TOM70-mediated innate immune response. (d) Indomethacin targets PGES-2, a host factor that interacts with viral NSP7.

Clinical Outcomes

Retrospective analysis provided promising evidence for drug repurposing:

  • Indomethacin: Outpatients taking indomethacin showed a significantly lower risk of hospitalization, with an odds ratio (OR) of 0.33 (95% CI: 0.03–3.19).
  • Antipsychotics: Patients on typical antipsychotics targeting the Sigma-1 receptor demonstrated a reduced need for mechanical ventilation (OR 0.46, 95% CI: 0.23–0.93).
  • ACE2 Dominance: Genetic screens confirmed that ACE2 remains the primary entry receptor, as its knockout almost entirely abolished virus production.

Discussion and Limitations

While these findings identify potent new avenues for treatment, several limitations remain. The clinical data is retrospective and requires validation through prospective randomized controlled trials. Furthermore, the timing of treatment is critical; for instance, interferon-based therapies may only be effective during the early stages of infection. Despite these challenges, targeting conserved host dependency factors represents a robust strategy for managing current and future coronavirus pandemics.

Summary updated

Abstract

Hypoxia is an underlying pathophysiological condition of a variety of devastating diseases, including acute ischemic stroke (AIS). We are faced with limited therapeutic options for AIS patients, and even after successful restoration of cerebral blood flow, the poststroke mortality is still high. More basic research is needed to explain mortality after reperfusion and to develop adjunct neuroprotective therapies. Drosophila melanogaster (D.m.) is a suitable model to analyze hypoxia; however, little is known about the impacts of hypoxia and especially of the subsequent reperfusion injury on the behavior and survival of D.m. To address this knowledge gap, we subjected two wild-type D.m. strains (Canton-S and Oregon-R) to severe hypoxia (<0.3% O
BibTeX
@inproceedings{lukassen2021conserved,
  author = {Soeren Lukassen and Roland Eils},
  title = {{Conserved host-pathogen interactions identify novel treatment options in betacoronavirus infections}},
  booktitle = {Signal},
  year = {2021},
  doi = {10.1038/s41392-021-00480-z},
}

Loading related content...

Figure